The tariff bomb of US President Donald Trump is also becoming a problem for Indian companies. Once again, Trump has threatened to impose a tariff of 25 per cent on the imports related to three big sector automobiles, semiconductor and pharma sector, although the picture of which countries it will be imposed has not been cleared. But its impact is visible on Indian companies associated with these sectors. Talk, there has been a sharp decline in the stocks associated with it on Wednesday. These include stocks ranging from Dr Reddy’s to Zydus Life.
This sector under 25% tariff pressure
Donald Trump has recently asked to impose a tariff of 25 % on the import of Auto, Semiconductor and Pharma product, so before this, US President has also announced high tariff on steel and aluminum imports and it should be implemented from March 2025 Can The worst effect of Trump Tariff has been seen on the shares of pharmaceutical companies. On Wednesday, during the early trade in the stock market, the NIFTY PHARMA index slipped about 3 percent.
Pharma shares kept trading in the decline throughout the day
Talking about a decline in pharma companies, during trading on Wednesday, Dr Reddy’s Lab Share opened at Rs 1166 against its previous bandh and slipped about 5 per cent to Rs 1127. Apart from this, the stock of Zydus Lifescienes came up to Rs 855 after the stock was opened at Rs 890. At the same time, Aurobindo Pharma’s stock slipped more than 7 percent in early trade.
Apart from this, Lupin Share also saw a sharp decline and after opening at Rs 1950, it slipped to Rs 1892 to Rs 1892. The shares of Abbott Lab also saw a decline around 1 percent.
Indian pharmaceutical business in America
President Donald Trump has recently said that tariffs on pharma and semiconductor chips can be 25 percent or more. After this, pharma stocks have dived. The reason behind this is that these companies have a big business in America. Indian pharma companies supply generic drugs around 60 per cent to the US, which are helpful in reducing the cost of health service. However, the plan to impose 25% tariff on imported medicines has created concerns for drug manufacturers.
(Note- Be sure to consult your market experts before any investment in the stock market.)